title: Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline.
abstract: METHODS
  In December 2014, the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the management of dyslipidemia for cardiovascular disease risk reduction in adults. This synopsis summarizes the major recommendations.
  
  
  METHODS
  On 30 September 2013, the VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included clinical stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions, systematically searched and evaluated the literature, developed a simple 1-page algorithm, and rated each of 26 recommendations by using the Grading of Recommendations Assessment, Development, and Evaluation system.
  
  
  CONCLUSIONS
  This synopsis summarizes key features of the guideline in 5 areas: elimination of treatment targets, additional tests for risk prediction, primary and secondary prevention, and laboratory testing.
authors.forename: John R
authors.initials: JR
authors.lastname: Downs
authors.forename: Patrick G
authors.initials: PG
authors.lastname: O'Malley
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D050171:Dyslipidemias / Q000175:diagnosis / Q000188:drug therapy*; D006403:Hematologic Tests; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D011322:Primary Prevention; D040242:Risk Reduction Behavior; D055502:Secondary Prevention; D014481:United States; D059030:United States Department of Defense; D014493:United States Department of Veterans Affairs
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors